Last reviewed · How we verify
NCT03827525: WILL-COPE
Cognitive and Behavioral Therapy of Anxiety in Williams Syndrome
trial testing Cognitive and Behavioral Therapy in Williams Syndrome in 5 participants. Status unknown.
29 April 2021
Quick facts
| Lead sponsor | University Hospital, Montpellier |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 5 |
| Start date | 29 August 2019 |
| Primary completion | 29 April 2021 |
| Estimated completion | 29 April 2021 |
| Sites | 1 location across France |
Drugs / interventions tested
- Cognitive and Behavioral Therapy
Conditions studied
- Williams Syndrome — all drugs for Williams Syndrome →
- Anxiety — all drugs for Anxiety →
Sponsor
University Hospital, Montpellier
Who can join
18 and older, any sex, with Williams Syndrome or Anxiety. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Patients with Williams-Beuren syndrome are eight times more likely to suffer from anxiety compared to the general population. Few therapeutic solutions are proposed to these patients. The objective of this research is to validate a cognitive and behavioral therapy anxiety protocol for patients with this syndrome.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Evaluation of the Effectiveness of Therapy for Anxiety in Williams Beuren Syndrome Using a Smartphone App: Protocol for a Single-Case Experiment.
Lehman N, Trouillet R, Genevieve D. · · 2023 · PMID 37010888 · DOI 10.2196/44393
Verify or expand the search:
- PubMed search for NCT03827525
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Cognitive and Behavioral Therapy
Trials testing the same drug.
- NCT04626570 — Impact of a Phone-based Cognitive and Behavioral Therapy on Food Addiction in Patients With Severe or Morbid Obesity · NA · completed
Other recruiting trials for Williams Syndrome
Currently open trials in the same condition.
- NCT07493096 — Intensive Multimodal Neurorehabilitation Targeting Neuroplasticity in Pediatric Neurodevelopmental and Chromosomal Disor · recruiting
- NCT06930417 — Characterization and Natural History of Williams Syndrome and Other Chromosome 7q11.23 Variants · recruiting
- NCT02706639 — Williams Syndrome (WS) and Supravalvar Aortic Stenosis (SVAS) DNA and Tissue Bank · recruiting
- NCT01132885 — Defining the Brain Phenotype of Children With Williams Syndrome · recruiting
Other University Hospital, Montpellier trials
Trials by the same sponsor.
- NCT07524127 — Phenotyping of Type 2 Inflammation Profile by Rheology of Nasal Secretions and Tissue Quantification of Eosinophilic Pol · NA · not yet recruiting
- NCT07255495 — Effects of Neuromuscular Scoliosis Surgery on Nutritional Metabolism · NA · not yet recruiting
- NCT07534189 — Prospective Cohort Study Evaluating a Thermal Spa Programme in Symptomatic Knee Osteoarthritis · NA · not yet recruiting
- NCT07515638 — Immun4Cure Cohort of Autoimmune Diseases · not yet recruiting
- NCT07406516 — Identification of Kinematic Variables Specific of Patellar Tendinopathy in Athletes at Risk · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03827525 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University Hospital, Montpellier
- Last refreshed: 18 October 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03827525.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing